10 Best Stocks to Buy for the Next Decade

In this article, we will look at the 10 Best Stocks to Buy for the Next Decade.

A 10-year investing horizon shifts the conversation away from short-term noise toward something more durable: which businesses can keep growing, adapting, and compounding through different market environments. Franklin Templeton says markets are “transitioning from a narrow, liquidity-driven regime to one shaped by fundamentals, innovation, and active management,” which is another way of saying the next stretch may reward business quality more than simple momentum. For long-term investors, this shift is worth watching.

The institutional case for owning quality stocks over the long run is clear. Fidelity points investors toward “best-in-class companies” with “deep competitive moats” and says stocks with “long-term growth potential” can “compound earnings over time.” J.P. Morgan Asset Management adds that “High quality stocks are now priced at a discount,” and says the quality factor in U.S. markets is “more attractive than ever” outside unusually dislocated periods. Franklin Templeton makes the same argument from a longer-cycle perspective, emphasizing “high-quality growth companies with durable competitive advantages” and a process aimed at “sustainable alpha across cycles.” The best decade-long ideas are usually not the flashiest ones, but the companies with staying power, pricing power, and room to keep building value.

Against this backdrop, we will look at the 10 Best Stocks to Buy for the Next Decade.

Our Methodology

We used the Finviz screener to identify high-quality stocks that exhibited over 20% EPS annual growth over the last 5 years and are forecasted to grow EPS annually by over 20% in the next 5 years. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

10. Eli Lilly and Company (NYSE:LLY)

On April 15, 2026, Eli Lilly and Company (NYSE:LLY) disclosed that the U.S. FDA had requested additional data related to potential liver injury associated with its newly approved obesity pill, along with post-marketing studies on cardiovascular risks and gastric emptying, according to a Reuters report. The agency also required a lactation study as part of its ongoing safety monitoring under the drug’s priority review approval. A Lilly spokesperson said there were no indications of liver damage in late-stage trials, adding that “The FDA approved Foundayo based on its review of data from the ATTAIN clinical program,” with post-approval requirements consistent with standard safety evaluation practices.

On April 12, 2026, Lilly reported topline results from the Phase 3 BRUIN CLL-322 trial evaluating Jaypirca, a non-covalent Bruton tyrosine kinase inhibitor, in combination with venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival versus venetoclax and rituximab alone, with results consistent across key subgroups, including patients previously treated with a covalent BTK inhibitor. Overall survival data were not yet mature but trended in favor of the combination regimen, while the safety profile remained consistent with known profiles, and discontinuation rates were low across both arms. Lilly plans to present detailed data at a medical conference and submit findings to regulators for potential label expansion later this year.

On April 9, 2026, Morgan Stanley raised its price target on Eli Lilly to $1,327 from $1,313 and maintained an Overweight rating, reflecting model updates across its biopharma coverage ahead of Q1 earnings.

Eli Lilly and Company (NYSE:LLY) develops and markets pharmaceutical products globally.

9. Amphenol Corporation (NYSE:APH)

On April 14, 2026, UBS lowered its price target on Amphenol Corporation (NYSE:APH) to $170 from $174 and maintained a Buy rating. The firm said valuations have become more reasonable after turning cautious following Q4 results and 2026 guidance, which had highlighted limited upside and reliance on multiple expansion. UBS added that while demand concerns and potential production cuts could weigh on sentiment and near-term margins may face pressure from inflation, expectations have already reset lower, suggesting that even modest estimate cuts or reaffirmed guidance could be received positively by investors.

On April 8, 2026, Citi lowered its price target on Amphenol to $170 from $180 and kept a Buy rating. The firm noted that copper interconnect names have seen multiple compressions as the shift toward optical interconnect accelerates, but said the recent selloff in Amphenol presents an “attractive setup,” supported by constructive data center demand commentary during Q1.

Earlier, following its acquisition of the Connectivity and Cable Solutions business from Vistance Networks, Amphenol launched an open offer to acquire up to 1,196,000 equity shares of ADC India Communications, representing 26.0% of the company’s voting share capital, from public shareholders. The tendering period runs from April 2 to April 17, 2026, in accordance with SEBI regulations. The offer price is INR 1,233.59 per share, implying a total cash consideration of approximately INR 1.48B, assuming full acceptance. The open offer, which is not subject to a minimum acceptance threshold, was triggered by Amphenol’s indirect acquisition of control of the target company under a purchase agreement dated August 3, 2025, and follows the completion of the CCS acquisition, after which ADC India became an indirect majority-owned subsidiary.

Amphenol Corporation (NYSE:APH) manufactures connectors and interconnect systems globally.

8. Carpenter Technology Corporation (NYSE:CRS)

On April 8, 2026, KeyBanc raised its price target on Carpenter Technology Corporation (NYSE:CRS) to $453 from $380 and maintained an Overweight rating. The firm cited findings from its proprietary Q1 Plane Chain survey, which indicated a meaningful step-up in OEM order activity as aerospace production recovery gains momentum. KeyBanc noted that supplier inventories are beginning to restock to support ongoing production ramps, while tight conditions in the aerospace and defense aftermarket are extending fleet life. The firm added that geopolitical tensions, including the Iran conflict, are supporting defense demand, though elevated fuel costs remain a key risk, potentially pressuring air travel demand and pushing airlines toward lower-cost alternatives.

Last month, Wells Fargo initiated coverage of Carpenter Technology with an Equal Weight rating and a $400 price target, warning that pricing gains may moderate due to increased capacity and a higher mix of fixed-price contracts, which could limit upside to future guidance.

Meanwhile, Susquehanna analyst Charles Minervino initiated coverage with a Positive rating and a $470 price target, highlighting Carpenter’s role as a supplier of specialized alloys into what it described as a “thriving” aerospace and defense market. The firm pointed to strong order activity, rising commercial aircraft production rates, and growing demand for advanced metallurgy, particularly in defense applications. Susquehanna also emphasized Carpenter’s solid balance sheet and liquidity position, which it believes support continued investment in growth, dividend increases, and share repurchases.

Carpenter Technology Corporation (NYSE:CRS) manufactures specialty metals and alloys for industrial applications worldwide.

7. First Solar, Inc. (NASDAQ:FSLR)

On April 8, 2026, Susquehanna lowered its price target on First Solar, Inc. (NASDAQ:FSLR) to $250 from $280 previously and maintained a Positive rating on the shares as part of a broader update to estimates ahead of Q1 earnings across its alternative energy coverage.

On April 6, 2026, Jefferies analyst Julien Dumoulin-Smith cut the firm’s price target on First Solar, Inc. (NASDAQ:FSLR) to $187 from $205 previously and kept a Hold rating on the shares. The firm flagged rising concerns around inflationary logistics costs linked to the Middle East conflict, which could pressure near-term margins, and accordingly lowered its FY26 margin outlook for the company.

Last month, Guggenheim analyst Joseph Osha reduced the price target on First Solar, Inc. (NASDAQ:FSLR) to $269 from $312 previously and maintained a Buy rating on the shares after updating estimates.

First Solar, Inc. (NASDAQ:FSLR) develops and provides photovoltaic solar energy solutions.

6. Nucor Corporation (NYSE:NUE)

On April 15, 2026, Wells Fargo raised its price target on Nucor Corporation (NYSE:NUE) to $213 from $197 and maintained an Overweight rating, saying it has become more constructive on steel and aluminum heading into Q1 results, while taking a more selective stance on copper.

On April 14, 2026, JPMorgan raised its price target on Nucor to $212 from $198 and kept an Overweight rating as part of a broader Q1 preview for the North American steel group. The firm said a combination of “tight” supply and “mixed demand” conditions should remain supportive for the sector.

On March 31, 2026, Goldman Sachs analyst Nick Cash assumed coverage of Nucor with a Buy rating and a $210 price target, citing a bullish view on U.S. steel equities driven by sustained higher pricing tied to Section 232 tariffs, which have raised import costs and constrained supply. Goldman also pointed to above-average demand growth in infrastructure and pockets of strength in private non-residential construction, while favoring lower-beta companies with the potential to expand free cash flow and margins through product diversification and improving metal spreads.

Earlier in March, Nucor guided that first-quarter 2026 earnings are expected to increase across all three operating segments compared to Q4 2025, with the largest improvement in the steel mills segment due to higher average selling prices and volumes. The steel products segment is expected to benefit from increased volumes and stable pricing, while the raw materials segment is projected to post slightly higher earnings.

Nucor Corporation (NYSE:NUE) produces and sells steel and steel-related products.

Click to continue reading and see the 5 Best Stocks to Buy for the Next Decade.

Disclosure: None. Follow Insider Monkey on Google News.